Coverage and savings support

With MOTPOLY XR Copay Savings, patients pay as little as $10 per month on their MOTPOLY XR prescriptions*

Not an actual
patient.

Visit MotpolyXR.com for details and information about patient support.

* Subject to eligibility. Governmental beneficiaries excluded.
Restrictions apply.

AUCTA Pharmaceuticals

Patient Assistance Program

Aucta Pharmaceuticals is committed to providing support for people requiring MOTPOLY XR. If your patient is experiencing financial hardship or have limited or no insurance, your patient may be eligible to receive assistance through the Aucta Patient Assistance Program.

To find out if your patient is eligible and to complete the application, download the Aucta PAP Program Information and Application.

For eligibility questions or application support, please call (888) 656-0126.

Patient Assistance Program

PAP Application

download

Physician Resources

The resources provided are designed to help you counsel your young and adult patients with partial‑onset seizures and primary generalized tonic‑clonic seizures. Additional resources will be added in the future, so please check back regularly for more.

medical exception letter

Medical Exception Letter

Full Prescribing Information

Full Prescribing Information

Medication Guide

Medication Guide

Back to School - College

Take a Closer Look at Your Busy Young Adult Patients

download

INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.
MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction. Closely monitor these patients.
MOTPOLY XR may cause syncope.
Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

USE IN SPECIFIC POPULATIONS:

Dose adjustment is recommended for severe renal impairment and mild or moderate hepatic impairment. Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.
Use is not recommended in severe hepatic impairment.
Based on animal data, MOTPOLY XR may cause fetal harm if used in pregnancy.

Please refer to the full Prescribing Information and Medication Guide for MOTPOLY XR for additional important information.